AI is driving down the price of knowledge – universities have to rethink what they offer 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
The Beauty Beneath the Expressway: A Journey from Self to Service 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Why financial hardship is more likely if you’re disabled or sick 
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right 
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
